MARKET

FIXX

FIXX

Homology Medicines
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.02
+0.22
+1.99%
After Hours: 11.10 +0.09 +0.77% 18:17 09/25 EDT
OPEN
10.80
PREV CLOSE
10.80
HIGH
11.03
LOW
10.60
VOLUME
317.63K
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
9.19
MARKET CAP
498.08M
P/E (TTM)
-3.9497
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Homology Medicines to Participate in Upcoming Conferences
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual conferences: * Oppenheimer Fall Healthcare Life Sciences & MedTech Summit o Fireside Chat: September 22 at
GlobeNewswire · 09/18 13:00
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
Seeking Alpha - Article · 08/25 17:24
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates
Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 21:35
Homology Medicines Q2 EPS $(0.78) Down From $(0.61) YoY, Sales $567.00K Up From $392.00K YoY
Homology Medicines (NASDAQ:FIXX) reported quarterly losses of $(0.78) per share. This is a 27.87 percent decrease over losses of $(0.61) per share from the same period last year. The company reported $567.00 thousand in
Benzinga · 08/10 20:30
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key DataSuccessfully Executed Multiple Internal 2,000-Liter Bioreactor
GlobeNewswire · 08/10 20:05
Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to Decline
Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/06 16:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FIXX. Analyze the recent business situations of Homology Medicines through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FIXX stock price target is 30.22 with a high estimate of 37.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 138
Institutional Holdings: 37.91M
% Owned: 83.84%
Shares Outstanding: 45.22M
TypeInstitutionsShares
Increased
52
3.86M
New
37
-2.22M
Decreased
14
978.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Director/Primary Contact
Arthur Tzianabos
Chief Financial Officer/Treasurer/Secretary
W. Bradford Smith
Chief Scientific Officer
Albert Seymour
Chief Operating Officer
Sam Rasty
Other
Gabriel Cohn
Other
Tim Kelly
Director
Jeffrey Poulton
Independent Director
Steven Gillis
Independent Director
Richard Gregory
Independent Director
Kush Parmar
Independent Director
Matthew Patterson
Independent Director
Alise Reicin
Independent Director
Mary Thistle
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FIXX
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Homology Medicines Inc stock information, including NASDAQ:FIXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FIXX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FIXX stock methods without spending real money on the virtual paper trading platform.